Study F1K-MC-EVAD: Relative Risk under Original and Amended Protocols

10/17/01


Click here to start


Table of Contents

Study F1K-MC-EVAD: Relative Risk under Original and Amended Protocols

Study F1K-MC-EVAD: Relative Risk by Site Enrollment

Study F1K-MC-EVAD: Mortality by Type of Clinical Trial Material

Study F1K-MC-EVAD: Cox Regression Analysis by Baseline and Any Heparin Exposure Placebo Patients

Study F1K-MC-EVAD: Patient Populations within First APACHE II Quartile IL-6 Level

Study F1K-MC-EVAD: Location and Functional Status Original vs Amended Protocol

Study F1K-MC-EVAD: Safeguards to Maintain Study Blind during Conduct of Interim Analyses

Study F1K-MC-EVAD: Mortality by Adequate Use of Antibiotics (CEC)

Study F1K-MC-EVAD: Mortality by Culture or Blood Culture (CEC)

Study F1K-MC-EVAD: Stepwise Multiple Logistic Regression

Study F1K-MC-EVAD: Stepwise Multiple Logistic Regression

PPT Slide

Study F1K-MC-EVAD: Stepwise Multiple Logistic Regression Results

Study F1K-MC-EVAD: Data Safety Monitoring Board Members

Study F1K-MC-EVAD: Cumulative Mortality

Study F1K-MC-EVAD: Cumulative Mortality Sites Enrolling under Original and Amended Protocols

Why not a randomized controlled trial in kids?

Controlled Trial Sample Size Estimates

Studies F1K-MC-EVAO/EVAD: Number of Organ Failures at Baseline Pediatric versus Adult Patients

Studies F1K-MC-EVAO/EVAD: Type of Organ Failure at Baseline Pediatric versus Adult Patients

Studies F1K-MC-EVAO/EVAD: Percent of Patients with Positive Cultures at Baseline

Reporting of Adverse Events Study F1K-MC-EVAO versus Study F1K-MC-EVAD

Study F1K-MC-EVAO: Adverse Events Occurring in ?5% of Patients Part 2

Study F1K-MC-EVAO: Baseline Organ Failures for Selected Safety Categories

Study F1K-MC-EVAO: Intracerebral Hemorrhage Patient Scenario 1

Study F1K-MC-EVAD: Location Prior to Hospitalization First APACHE II Quartile

Author: RM87179